OOIR: Observatory of International Research

Papers

(The TQCC of Xenobiotica is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Academic foreign compound metabolism – ‘ quo vadis ’?	23
One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development	23
Developmental stage and infection status may affect drug distribution in the prostate of rats	20
In vitro hepatic metabolism of the natural product quebecol	17
Meeting report: oligonucleotide ADME workshop	15
Diisononyl phthalate down-regulates the expression of antioxidant genes NFE2L2 , TXN , and TXNRD2 , while d	13
Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver	12
Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2	12
Apigenin derivatives as promising norovirus RdRp inhibitors: insights from in silico docking and molecular dynamics studies	11
Nrf2 signaling pathway studies in Drosophila melanogaster : parallel roles in human health and insect environmental responses	11
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor	9
An In silico model-based feasibility assessment of erlotinib long-acting injectable formulation for the management of metastatic non-small cell lung cancer	9
Comparisons between human and rodent hepatic glutathione S-Transferase activities reveal sex and species differences	9
Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model	9
The protective effect of linalool against carbon tetrachloride-induced testicular toxicity in rats	9
Formulation of apigenin-loaded solid lipid nanoparticles: characterisation, molecular docking, and anticancer assay	9
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 1 and 2 (rs4244285, 681G>A) alleles in vitro	8
Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation	8
Exploring precision-cut liver slices for comparative xenobiotic metabolism profiling in swine and cattle	8
Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions	8
Preparation, characterisation, pharmacokinetics and distribution of esculin microspheres administered via intravitreal injection into rabbit brain	8
The effect of ARVs on the MEKKK1 gene promoter, inflammatory cytokine expression and signalling in acute treated Jurkat T cells	8
Arctigenin-induced erythrocyte membrane remodelling is mediated through calcium influx, metabolic collapse, and casein kinase 1α	8
Methyl mercury pharmacokinetics in man: a five-compartment hybrid model	8
Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers	8

Machine learning-driven bioavailability prediction in early-stage drug development: a KNIME-based computational workflow for digital health applications	8
An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds	7
In vivo evaluation of pharmacokinetic drug–drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin	7
New era in bioequivalence global harmonization through ICH M13 initiative: critical review on new concepts, alternative approaches for high-risk products	7
Preclinical pharmacokinetic investigation of the bioavailability and skin distribution of HY-072808 ointment, a novel drug candidate for the treatment of atopic dermatitis, in minipigs by a newly LC-M	7
Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats	7
Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P ₁ modulator ponesimod	7
Safflower yellow for injection enhances anti-coagulation of warfarin in rats: implications in pharmacodynamics and pharmacokinetics	7
Mechanism of Black American Ginseng saponins in ameliorating memory dysfunction in aging mice by activating the BDNF/PI3K/AKT/CREB pathway	7
Coptisine modulates the pharmacokinetics of florfenicol by targeting CYP1A2, CYP2C11 and CYP3A1 in the liver and P-gp in the jejunum of rats: a pilot study	6
Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson’s drug FLZ after multi-dose in cynomolgus monkeys	6
Bioavailability and dose proportionality of a highly lipophilic phenolic antioxidant	6
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir	6
Prediction of the neurotoxic mechanisms of the pesticide phorate using network toxicology, molecular docking, and molecular dynamics simulation	6
Defining the enzymes of xenobiotic metabolism – a forlorn hope?	6
Experimental and computational models to investigate intestinal drug permeability and metabolism	6
Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?	6
Effectiveness of pain care intervention combined with traditional Chinese medicine care in the perioperative care of patients with urinary stones	6
Nano-pharmacokinetics and pharmacodynamics of green-synthesized ZnO nanoparticles: a pathway to safer therapeutic applications	6
2-Oxidation, 3-methyl hydroxylation, and 6-hydroxylation of skatole, a contributor to the odour of boar-tainted pork meat, mediated by porcine liver microsomal cytochromes P450 1A2, 2A19, 2E1, and 3A2	6
Development of eugenol-fortified fisetin-loaded nano-invasomes gel	6
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human	6
Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities	6
Interactions of organophosphorus pesticides with ATP-binding cassette (ABC) drug transporters	6
The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma	6
Beyond cytotoxic potency: disposition features required to design ADC payload	6
Impact of tectoridin on the pharmacokinetics of florfenicol via targeting cytochrome P450 and P-glycoprotein of rats	5
Species differences in liver microsomal hydrolysis of acyl glucuronide in humans and rats	5
Characterisation of seven medications approved for attention-deficit/hyperactivity disorder usingin vitromodels of hepatic metabolism	5
Human and nonclinical disposition of [¹⁴C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection	5
Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation	5
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective	5
Sodium dodecylbenzene sulphonate (SDBS) present in detergents: action on the gills, skin, and blood of D. rerio fish	5
Pharmacokinetics of intranasal drugs, still a missed opportunity?	5
Preface for special issue: “Emerging strategies, technologies, and approaches for the next generation ADCs”	5
Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species	5
Sanguinarine-induced proteomic changes in methicillin-resistant Staphylococcus aureus	5
Meeting report of the 3rd European Biotransformation Workshop	5
Physiologically based pharmacokinetic (PBPK) modelling and simulation based integrative approach to assess natural product-drug interactions – effect of glycyrrhetinic acid on quetiapine	4
Meeting report: DMDG peptide and oligonucleotide ADME workshop 2024	4
Drug-drug interaction between danshensu and irbesartan and its potential mechanism	4
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects	4
The impact of CYP3A5 , NR1I2 , and POR polymorphisms on tacrolimus dose-adjusted concentration and clinical	4
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities	4
How predictive are isolated perfused liver data of in vivo hepatic clearance? A meta-analysis of isolated perfused rat liver data	4
Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury	4
Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration	4
Studies addressing potential bioactivation and genotoxicity liabilities of the N -nitroso derivative of the antidepressant paroxetine	4
The mitochondrial protective mechanisms mediated by SGLT2i: from molecular basis to clinical implications	4
In vitro evaluation of norwogonin as a potential inhibitor of cytochrome P450 forms 3A4, 2D6, and 2C9	4

Exploring the clinical pharmacokinetics and pharmacodynamics of third-generation cephalosporin, a cefotaxime: a systematic review	4
A physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the insecticide dimethoate	4
Use of a machine learning approach to estimate pathobiological effects of crack cocaine administration in rats	4
Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats	4
Study of the urinary metabolites of 17ɑ-methyl-19-nortestosterone in human using gas chromatography – mass spectrometry. Preliminary results	4
Perspectives on the use of machine learning for ADME prediction at AstraZeneca	4
Inorganic mercury pharmacokinetics in man: a hybrid model	4
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)	4